title: [Highly effective drug without modifying the lipid profile. Atazanavir, the protease inhibitor for "once daily" administration].
mesh_terms: D000480:Alkynes; D000069446:Atazanavir Sulfate; D048588:Benzoxazines; D002986:Clinical Trials as Topic; D003521:Cyclopropanes; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D017277:Drug Approval; D015658:HIV Infections / Q000097:blood / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D008055:Lipids / Q000097:blood*; D019888:Nelfinavir / Q000008:administration & dosage / Q000009:adverse effects; D009842:Oligopeptides / Q000008:administration & dosage* / Q000009:adverse effects; D010078:Oxazines / Q000008:administration & dosage / Q000009:adverse effects; D011725:Pyridines / Q000008:administration & dosage* / Q000009:adverse effects
chemical_list: D000480:Alkynes; D048588:Benzoxazines; D003521:Cyclopropanes; D017320:HIV Protease Inhibitors; D008055:Lipids; D009842:Oligopeptides; D010078:Oxazines; D011725:Pyridines; D000069446:Atazanavir Sulfate; D019888:Nelfinavir; C098320:efavirenz